Literature DB >> 26252844

Difference in Time to Locoregional Recurrence Between Patients With Right-Sided and Left-Sided Colon Cancers.

Jung Hun Park1, Min Jung Kim, Sung Chan Park, Min Ju Kim, Chang Won Hong, Dae Kyung Sohn, Kyung Su Han, Jae Hwan Oh.   

Abstract

BACKGROUND: Locoregional recurrence rates after curative resection for colon cancer vary widely. Identification of factors associated with locoregional recurrence may help in patient management.
OBJECTIVE: The purpose of this study was to compare time to locoregional recurrence and distribution of locoregional recurrence after curative resection of colon cancer according to primary tumor location and to investigate risk factors for locoregional recurrence of colon cancer.
DESIGN: This was a retrospective observational study. SETTINGS: This study was conducted at a single institution. PATIENTS: This study analyzed 1632 patients with colonic adenocarcinoma without distant metastasis who underwent curative resection at the National Cancer Center in Korea between January 2001 and December 2009. The primary end point of the study was time from surgery to locoregional recurrence. The Kaplan-Meier method was used to estimate the cumulative incidence of locoregional recurrence, and the log-rank test was used to test the difference in time to locoregional recurrence between patient subgroups. Cox proportional hazards models were used to investigate the risk factors for locoregional recurrence. MAIN OUTCOME MEASURES: The time from surgery to locoregional recurrence was compared between patients with right-sided and left-sided colon cancers.
RESULTS: The time to locoregional recurrence was significantly different between patients with right-sided and left-sided colon cancers (HR = 2.35 for right-sided; p < 0.001). The overall 5-year locoregional recurrence rate was 5.7%, and that in patients with right-sided and left-sided colon cancers was 8.5% and 4.1%. Multivariable analysis demonstrated that right-sided location, female sex, T4 disease, lymph node metastasis, and perineural invasion were independent risk factors for locoregional recurrence of colon cancer. LIMITATIONS: This was a retrospective design and single-institution study.
CONCLUSIONS: Patients with right-sided colon cancers presented with significantly increased risk of locoregional recurrence. Right-sided location, female sex, T4 disease, lymph node metastasis, and perineural invasion are independent risk factors for locoregional recurrence of colon cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26252844     DOI: 10.1097/DCR.0000000000000426

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

1.  Myeloperoxidase expression in human colonic mucosa is related to systemic oxidative balance in healthy subjects.

Authors:  Stefano Mancini; Francesco Mariani; Paola Sena; Marta Benincasa; Luca Roncucci
Journal:  Redox Rep       Date:  2017-01-09       Impact factor: 4.412

2.  Outcomes of laparoscopic surgery in pathologic T4 colon cancers compared to those of open surgery.

Authors:  Jeonghyun Kang; Seung Hyuk Baik; Kang Young Lee; Seung-Kook Sohn
Journal:  Int J Colorectal Dis       Date:  2016-11-23       Impact factor: 2.571

3.  High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.

Authors:  Sandrine Nugteren; Sjoerd H den Uil; Pien M Delis-van Diemen; Ytje Simons-Oosterhuis; Dicky J Lindenbergh-Kortleve; Daniëlle H van Haaften; Hein B A C Stockmann; Joyce Sanders; Gerrit A Meijer; Remond J A Fijneman; Janneke N Samsom
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 4.  Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Paolo Sammartino; Daniele Biacchi; Tommaso Cornali; Maurizio Cardi; Fabio Accarpio; Alessio Impagnatiello; Bianca Maria Sollazzo; Angelo Di Giorgio
Journal:  Indian J Surg Oncol       Date:  2016-01-26

5.  Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

Authors:  Sjoerd H den Uil; Veerle M H Coupé; Janneke F Linnekamp; Evert van den Broek; Jeroen A C M Goos; Pien M Delis-van Diemen; Eric J Th Belt; Nicole C T van Grieken; Patricia M Scott; Louis Vermeulen; Jan Paul Medema; Herman Bril; Hein B A C Stockmann; Robert T Cormier; Gerrit A Meijer; Remond J A Fijneman
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

6.  Clinical significance of circulating immune cells in left- and right-sided colon cancer.

Authors:  Jiabo Di; Meng Zhuang; Hong Yang; Beihai Jiang; Zaozao Wang; Xiangqian Su
Journal:  PeerJ       Date:  2017-12-08       Impact factor: 2.984

7.  Comparison of survival between right-sided and left-sided colon cancer in different situations.

Authors:  Miao-Zhen Qiu; Wen-Tao Pan; Jun-Zhong Lin; Zi-Xian Wang; Zhi-Zhong Pan; Feng-Hua Wang; Da-Jun Yang; Rui-Hua Xu
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

8.  MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

Authors:  Evert van den Broek; Sjoerd H den Uil; Veerle M H Coupé; Pien M Delis-van Diemen; Anne S Bolijn; Herman Bril; Hein B A C Stockmann; Nicole C T van Grieken; Gerrit A Meijer; Remond J A Fijneman
Journal:  Oncotarget       Date:  2018-06-29

9.  Serum extracellular vesicles contain SPARC and LRG1 as biomarkers of colon cancer and differ by tumour primary location.

Authors:  Min-Er Zhong; Yanyu Chen; Yi Xiao; Lai Xu; Guannan Zhang; Junyang Lu; Huizhong Qiu; Wei Ge; Bin Wu
Journal:  EBioMedicine       Date:  2019-11-18       Impact factor: 8.143

10.  Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.

Authors:  Jiefu Wang; Jia Liu; Fei Tian; Yang Zhan; Dalu Kong
Journal:  Oncol Lett       Date:  2019-10-08       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.